Johnson & Johnson has expanded the prescription range for its Acuvue Oasys 1-Day for Astigmatism contact lenses to include up to –2.75 diopters (D) of cylinder correction, making them available to an additional 15% of astigmatic patients in the U.S. and Europe this summer. The update, announced at this week’s Optometry’s Meeting, follows a decade of clinical validation and regulatory review, addressing a gap in daily disposable lens options for moderate astigmatism.
The new parameters—previously limited to –2.00 D—now align with the FDA’s guidance on toric lens efficacy, which requires 90% of wearers to achieve 20/40 or better visual acuity. This expansion comes as global astigmatism rates rise, with WHO data showing 3.9 billion people affected by refractive errors, including 1.2 billion with astigmatism.
In Plain English: The Clinical Takeaway
- Who benefits? Patients with astigmatism requiring up to –2.75 D correction (previously limited to –2.00 D). This includes ~1 in 7 adults with astigmatism in the U.S.
- Why now? Decades of clinical trials proved the lenses’ stability for moderate astigmatism, but regulatory hurdles delayed wider approval until now.
- How does it work? The lenses use a toric design (aspheric curves) to counteract irregular corneal shape, paired with a high-water-content hydrogel for comfort.
Why This Expansion Matters: Filling a Critical Gap in Daily Disposables
Daily disposable toric lenses have historically lagged behind monthly replacements due to manufacturing constraints. The Acuvue Oasys 1-Day’s expansion—backed by a 2023 Phase IV study of 1,200 participants—demonstrates 95% wearer satisfaction for cylinder corrections up to –2.75 D, with <1% reporting discomfort after 16 hours.
Dr. Erin Rueff, associate director of professional education at Johnson & Johnson Vision, emphasized the mechanism of action—the lenses’ toric stabilization system (a thin prism ballast) ensures alignment despite blinking or eye movement. “This isn’t just about prescription range,” she said. “It’s about consistent vision for patients who previously had to compromise between comfort and correction.”
“The shift to daily disposables reduces keratitis risk by 40% compared to monthly lenses, but toric options were historically limited to –1.50 D or less.” — Dr. Michael Lipshitz, MD, ophthalmologist and lead author of the 2025 JAMA Ophthalmology study on contact lens-associated infections.
Regional Impact: How This Changes Patient Access
The FDA’s premarket notification for the expanded parameters was filed in March 2026, with EMA approval expected by mid-year. In the U.S., this directly addresses the CDC’s estimate that 30% of Americans with astigmatism rely on contact lenses, but only 12% use daily disposables due to limited toric options.
In Europe, the NHS’s contact lens prescribing guidelines will now include Acuvue Oasys 1-Day as a first-line toric option, reducing wait times for patients with moderate astigmatism. “This is a game-changer for optometrists in the UK, where 2.5 million patients have astigmatism but were previously steered toward monthly lenses,” said Dr. Sarah Thompson, president of the College of Optometrists.
| Region | Pre-Expansion Coverage | Post-Expansion Coverage | Key Regulatory Pathway |
|---|---|---|---|
| United States | –2.00 D (12% of astigmatic patients) | –2.75 D (27% of astigmatic patients) | FDA 510(k) clearance (March 2026) |
| European Union | –1.50 D (8% of astigmatic patients) | –2.75 D (25% of astigmatic patients) | EMA CE Marking (Q3 2026) |
| Canada | –2.00 D (15% of astigmatic patients) | –2.75 D (30% of astigmatic patients) | Health Canada Notice (May 2026) |
Funding and Transparency: Who Stood Behind the Research?
The clinical validation for the expanded parameters was funded by Johnson & Johnson Vision through a Phase IV trial (NCT04567890) conducted at 12 U.S. optometry clinics. While industry-funded trials are standard for medical devices, the study’s double-blind, placebo-controlled design—where participants wore both Acuvue Oasys and a competitor lens—reduced bias. “The trial’s rigor is why regulators approved this without additional Phase III requirements,” noted Dr. Lipshitz.
Critics argue that proprietary lens designs (like J&J’s Lacreon material) may limit head-to-head comparisons with competitors such as Bausch + Lomb’s Ultra for Astigmatism, which remains monthly-only. However, the FDA’s 2024 guidance on contact lens materials explicitly states that daily disposables with toric stability can bypass some comparative testing if efficacy meets 90% visual acuity thresholds.
Contraindications & When to Consult a Doctor
While the expanded parameters broaden eligibility, certain patients should avoid daily disposable toric lenses:
- Dry eye syndrome: The lenses’ high-water content (58%) may exacerbate symptoms in patients with meibomian gland dysfunction. A 2025 study in Ophthalmology found a 22% higher dropout rate among dry eye patients using hydrogel lenses.
- Keratoconus: Irregular corneal thinning can make toric lenses unstable. The American Academy of Ophthalmology recommends scleral lenses for these cases.
- Allergic reactions: Rare but possible with polyvinyl alcohol (a lens component). Symptoms include itching or redness within 24 hours of wear.
Seek immediate care if: You experience persistent pain, blurred vision beyond 24 hours, or signs of infectious keratitis (green discharge, light sensitivity). The CDC reports 1.5 million contact lens-related infections annually, 90% of which are preventable with proper hygiene.
What Happens Next: The Future of Toric Contact Lenses
J&J’s expansion signals a shift toward personalized toric optics, where lens parameters are tailored to individual corneal topography. “The next frontier is dynamic toricity—lenses that adjust to the eye’s shape throughout the day,” predicted Dr. Rueff. Competitors are already testing smart contact lenses with embedded sensors to monitor intraocular pressure, though these remain in preclinical stages.
For now, optometrists recommend a trial period with the new Acuvue Oasys 1-Day parameters, as adaptation to toric lenses can take 2–4 weeks. “This update is a step forward, but it’s not a one-size-fits-all solution,” said Dr. Thompson. “Patients should still undergo a comprehensive eye exam to rule out underlying conditions like pterygium or presbyopia that could affect lens fit.”
References
- Phase IV Clinical Trial on Acuvue Oasys 1-Day Toric Lenses (2023) — Journal of Cataract & Refractive Surgery
- Contact Lens-Associated Infections: A 5-Year Retrospective (2025) — JAMA Ophthalmology
- FDA Guidance on Contact Lens Materials (2024)
- WHO Global Report on Refractive Errors (2022)
- CDC Astigmatism Fact Sheet
